Novel Therapeutic Targets in Liver Fibrosis
Liver fibrosis is end-stage liver disease that can be rescued. If irritation continues due to viral infection, schistosomiasis and alcoholism, liver fibrosis can progress to liver cirrhosis and even cancer. The US Food and Drug Administration has not approved any drugs that act directly against live...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/58f517150ba14c2e9fbd90e1f5c13c15 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:58f517150ba14c2e9fbd90e1f5c13c15 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:58f517150ba14c2e9fbd90e1f5c13c152021-11-05T10:41:53ZNovel Therapeutic Targets in Liver Fibrosis2296-889X10.3389/fmolb.2021.766855https://doaj.org/article/58f517150ba14c2e9fbd90e1f5c13c152021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmolb.2021.766855/fullhttps://doaj.org/toc/2296-889XLiver fibrosis is end-stage liver disease that can be rescued. If irritation continues due to viral infection, schistosomiasis and alcoholism, liver fibrosis can progress to liver cirrhosis and even cancer. The US Food and Drug Administration has not approved any drugs that act directly against liver fibrosis. The only treatments currently available are drugs that eliminate pathogenic factors, which show poor efficacy; and liver transplantation, which is expensive. This highlights the importance of clarifying the mechanism of liver fibrosis and searching for new treatments against it. This review summarizes how parenchymal, nonparenchymal cells, inflammatory cells and various processes (liver fibrosis, hepatic stellate cell activation, cell death and proliferation, deposition of extracellular matrix, cell metabolism, inflammation and epigenetics) contribute to liver fibrosis. We highlight discoveries of novel therapeutic targets, which may provide new insights into potential treatments for liver fibrosis.Jinhang ZhangQinhui LiuJinhan HeJinhan HeYanping LiFrontiers Media S.A.articleliver fibrosishepatic stellate cellstherapeutic targetsmolecular mechanismnon-alcocholic fatty liver diseaseBiology (General)QH301-705.5ENFrontiers in Molecular Biosciences, Vol 8 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
liver fibrosis hepatic stellate cells therapeutic targets molecular mechanism non-alcocholic fatty liver disease Biology (General) QH301-705.5 |
| spellingShingle |
liver fibrosis hepatic stellate cells therapeutic targets molecular mechanism non-alcocholic fatty liver disease Biology (General) QH301-705.5 Jinhang Zhang Qinhui Liu Jinhan He Jinhan He Yanping Li Novel Therapeutic Targets in Liver Fibrosis |
| description |
Liver fibrosis is end-stage liver disease that can be rescued. If irritation continues due to viral infection, schistosomiasis and alcoholism, liver fibrosis can progress to liver cirrhosis and even cancer. The US Food and Drug Administration has not approved any drugs that act directly against liver fibrosis. The only treatments currently available are drugs that eliminate pathogenic factors, which show poor efficacy; and liver transplantation, which is expensive. This highlights the importance of clarifying the mechanism of liver fibrosis and searching for new treatments against it. This review summarizes how parenchymal, nonparenchymal cells, inflammatory cells and various processes (liver fibrosis, hepatic stellate cell activation, cell death and proliferation, deposition of extracellular matrix, cell metabolism, inflammation and epigenetics) contribute to liver fibrosis. We highlight discoveries of novel therapeutic targets, which may provide new insights into potential treatments for liver fibrosis. |
| format |
article |
| author |
Jinhang Zhang Qinhui Liu Jinhan He Jinhan He Yanping Li |
| author_facet |
Jinhang Zhang Qinhui Liu Jinhan He Jinhan He Yanping Li |
| author_sort |
Jinhang Zhang |
| title |
Novel Therapeutic Targets in Liver Fibrosis |
| title_short |
Novel Therapeutic Targets in Liver Fibrosis |
| title_full |
Novel Therapeutic Targets in Liver Fibrosis |
| title_fullStr |
Novel Therapeutic Targets in Liver Fibrosis |
| title_full_unstemmed |
Novel Therapeutic Targets in Liver Fibrosis |
| title_sort |
novel therapeutic targets in liver fibrosis |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/58f517150ba14c2e9fbd90e1f5c13c15 |
| work_keys_str_mv |
AT jinhangzhang noveltherapeutictargetsinliverfibrosis AT qinhuiliu noveltherapeutictargetsinliverfibrosis AT jinhanhe noveltherapeutictargetsinliverfibrosis AT jinhanhe noveltherapeutictargetsinliverfibrosis AT yanpingli noveltherapeutictargetsinliverfibrosis |
| _version_ |
1718444290609250304 |